These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1894148)

  • 1. Liver enzyme abnormalities in Parkinson's disease.
    Tanner CM
    Geriatrics; 1991 Aug; 46 Suppl 1():60-3. PubMed ID: 1894148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look.
    Tanner CM
    Neurology; 1991 May; 41(5 Suppl 2):89-91; discussion 92. PubMed ID: 2041601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
    Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
    J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MPTP tale: pathway to prevention of Parkinson's disease?
    Williams A; Waring R
    Br J Hosp Med; 1993 May 19-Jun 1; 49(10):716-9. PubMed ID: 8324592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the oxidative polymorphism and early onset of Parkinson's disease.
    Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
    Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
    Kurth MC; Kurth JH
    Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C
    Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
    [No Abstract]   [Full Text] [Related]  

  • 8. Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats.
    Goralski KB; Renton KW
    Toxicol Appl Pharmacol; 2004 May; 196(3):381-9. PubMed ID: 15094308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P450 enzymes and Parkinson's disease: the story so far.
    Riedl AG; Watts PM; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):212-20. PubMed ID: 9539332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease.
    Factor SA; Weiner WJ; Hefti F
    Ann Neurol; 1989 Aug; 26(2):286-8. PubMed ID: 2774516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Jenner P
    Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms in Parkinson's disease.
    Checkoway H; Farin FM; Costa-Mallen P; Kirchner SC; Costa LG
    Neurotoxicology; 1998; 19(4-5):635-43. PubMed ID: 9745923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease.
    Ho SL; McCann KP; Bennett P; Kapadi AL; Waring RH; Ramsden DB; Williams AC
    Adv Neurol; 1996; 69():53-60. PubMed ID: 8615175
    [No Abstract]   [Full Text] [Related]  

  • 17. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
    Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC
    Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking, cancer, and Parkinson's disease.
    Barbeau A; Roy M; Cloutier T
    Ann Neurol; 1986 Jul; 20(1):105-6. PubMed ID: 3740811
    [No Abstract]   [Full Text] [Related]  

  • 19. Autotoxicity, methylation and a road to the prevention of Parkinson's disease.
    Williams AC; Ramsden DB
    J Clin Neurosci; 2005 Jan; 12(1):6-11. PubMed ID: 15639403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease].
    Tao E; Liu Z; Chen B; Pan X; Shao M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Oct; 15(5):281-3. PubMed ID: 9758873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.